Prestige Consumer Healthcare (PBH) Stock Price, News & Analysis

Company Overview

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Key Stats

• Today's Range: $66.33 to $67.61
• 50-Day Range: $64.04 to $84.73
• 52-Week Range: $62.95 to $90.04
• Volume: 381,142 shs
• Average Volume: 395,985 shs
• Market Capitalization: $3.33 billion
• P/E Ratio: 15.85
• Dividend Yield: N/A
• Price Target: $93.33
• Consensus Rating: Moderate Buy

Prestige Consumer Healthcare Stock Analysis - MarketRank™

Prestige Consumer Healthcare scored higher than 94% of companies evaluated by MarketBeat, and ranked 50th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Prestige Consumer Healthcare has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Prestige Consumer Healthcare has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.78%

Earnings Growth

Earnings for Prestige Consumer Healthcare are expected to grow by 5.78% in the coming year, from $4.50 to $4.76 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Prestige Consumer Healthcare is 15.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of Prestige Consumer Healthcare is 15.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.73.

Price to Earnings Growth Ratio

Prestige Consumer Healthcare has a PEG Ratio of 2.10. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Prestige Consumer Healthcare has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.68% of the float of Prestige Consumer Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Prestige Consumer Healthcare has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Prestige Consumer Healthcare has recently decreased by 13.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prestige Consumer Healthcare does not currently pay a dividend.

Dividend Growth

Prestige Consumer Healthcare does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -2.35

Percentage of Shares Shorted

2.68% of the float of Prestige Consumer Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Prestige Consumer Healthcare has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Prestige Consumer Healthcare has recently decreased by 13.91%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.60

News Sentiment

Prestige Consumer Healthcare has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Prestige Consumer Healthcare this week, compared to 6 articles on an average week.

Search Interest

Only 1 people have searched for PBH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prestige Consumer Healthcare insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.40% of the stock of Prestige Consumer Healthcare is held by insiders.

Percentage Held by Institutions

99.95% of the stock of Prestige Consumer Healthcare is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PBH Stock Analysis - Frequently Asked Questions

How have PBH shares performed this year?

Prestige Consumer Healthcare's stock was trading at $78.09 at the start of the year. Since then, PBH shares have decreased by 13.8% and is now trading at $67.2950.

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) announced its quarterly earnings data on Thursday, August, 7th. The company reported $0.95 EPS for the quarter, missing analysts' consensus estimates of $1.01 by $0.06. The company's quarterly revenue was down 6.6% on a year-over-year basis.
Read the conference call transcript.

Who are Prestige Consumer Healthcare's major shareholders?

Top institutional shareholders of Prestige Consumer Healthcare include Ariel Investments LLC (4.48%), State Street Corp (4.06%), Allspring Global Investments Holdings LLC (3.08%) and Geode Capital Management LLC (2.86%). Insiders that own company stock include Ronald M Lombardi, William P'pool, Adel Mekhail and Mary Beth Fritz.
View institutional ownership trends.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prestige Consumer Healthcare investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 8/28/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Personal Products
• Current Symbol: NYSE:PBH
• CIK: 1295947
• Web: www.prestigebrands.com
• Phone: (914) 524-6800
• Fax: 302-674-5266
• Employees: 540
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Prestige Consumer Healthcare: $93.33
• High Price Target: $104.00
• Low Price Target: $76.00
• Potential Upside/Downside: +38.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.26
• Trailing P/E Ratio: 15.81
• Forward P/E Ratio: 14.95
• P/E Growth: 2.1
• Net Income: $214.60 million
• Net Margins: 19.02%
• Pretax Margin: 25.67%
• Return on Equity: 12.69%
• Return on Assets: 6.79%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 4.38
• Quick Ratio: 2.99

Sales & Book Value

• Annual Sales: $1.14 billion
• Price / Sales: 2.91
• Cash Flow: $5.28 per share
• Price / Cash Flow: 12.74
• Book Value: $37.70 per share
• Price / Book: 1.79

Miscellaneous

• Outstanding Shares: 49,210,000
• Free Float: 48,525,000
• Market Cap: $3.31 billion
• Optionable: Optionable
• Beta: 0.43